First Trust Advisors LP lifted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 35.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 380,400 shares of the company’s stock after purchasing an additional 98,646 shares during the quarter. First Trust Advisors LP’s holdings in Eli Lilly And Co were worth $40,821,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Eli Lilly And Co during the second quarter worth about $114,000. Legacy Advisors LLC raised its position in shares of Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares during the period. Fort L.P. acquired a new stake in shares of Eli Lilly And Co during the second quarter worth about $121,000. Financial Management Professionals Inc. acquired a new stake in shares of Eli Lilly And Co during the second quarter worth about $128,000. Finally, Twin Tree Management LP raised its position in shares of Eli Lilly And Co by 97.9% during the second quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock worth $136,000 after purchasing an additional 786 shares during the period. 76.36% of the stock is currently owned by institutional investors.
A number of research firms have recently commented on LLY. Guggenheim began coverage on Eli Lilly And Co in a research report on Monday, October 8th. They set a “buy” rating on the stock. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Tuesday, October 9th. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Monday, October 8th. BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $107.00 to $130.00 in a research report on Thursday, October 4th. Finally, JPMorgan Chase & Co. set a $123.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a research report on Friday, October 5th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $111.53.
Shares of Eli Lilly And Co stock opened at $108.44 on Thursday. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $116.61. The company has a market capitalization of $116.36 billion, a P/E ratio of 21.54, a PEG ratio of 1.76 and a beta of 0.29. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Bear Market
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.